Skip to main content
Medical information Clinical review pending

Genetic Testing

PRRT2 Gene Convulsions Familial Infantile with Paroxysmal Choreoathetosis Genetic Test

Genetic test to identify mutations in the PRRT2 gene associated with familial infantile convulsions and paroxysmal choreoathetosis. Helps diagnose neurological disorders and guide treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or a single drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the test and create a family pedigree.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the PRRT2 Gene Convulsions Familial Infantile with Paroxysmal Choreoathetosis Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with recurrent seizures, especially starting in infancy.
  • ✓Patients presenting with paroxysmal choreoathetosis.
  • ✓Family history of familial infantile convulsions or paroxysmal choreoathetosis.
  • ✓Diagnosis of suspected PRRT2-related disorders.
  • ✓Genetic counseling for families with affected members.
  • ✓Understanding the genetic basis of neurological symptoms.
02

In plain language

What this test helps you understand

Identifies mutations in the PRRT2 gene linked to familial infantile convulsions and paroxysmal choreoathetosis. Aids in diagnosis, prognosis, and guiding treatment decisions for individuals with relevant neurological symptoms.
The PRRT2 Gene Convulsions Familial Infantile with Paroxysmal Choreoathetosis NGS Genetic DNA Test is a diagnostic tool used to identify specific genetic mutations linked to certain neurological disorders. This test focuses on the PRRT2 gene, mutations in which are associated with conditions like familial infantile convulsions and paroxysmal choreoathetosis, which can significantly impact an individual's health and quality of life.

This test utilizes Next-Generation Sequencing (NGS) technology to analyze DNA samples. By detecting mutations in the PRRT2 gene, healthcare providers can gain valuable insights into the underlying genetic cause of a patient's symptoms. This information is crucial for accurate diagnosis, understanding the condition, and developing appropriate management and treatment strategies.

This test is particularly relevant for individuals experiencing symptoms such as recurrent seizures, involuntary movements (choreoathetosis), or neurological symptoms that began in infancy. A family history of similar conditions may also indicate the need for this test. Consultation with a healthcare professional, such as a neurologist, is recommended to determine if this test is appropriate based on your specific clinical situation.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session is recommended prior to testing to discuss the test and create a family pedigree.
SampleBlood sample (EDTA tube), extracted DNA, or a single drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) of the PRRT2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the PRRT2 gene. It will not detect mutations in other genes that may cause similar symptoms. Results may be inconclusive in some cases. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The PRRT2 gene provides instructions for making a protein involved in brain development and function. Mutations in this gene are linked to specific neurological disorders.
This test is recommended for individuals with symptoms like recurrent seizures or involuntary movements (choreoathetosis), especially if they started in infancy or if there is a family history of similar conditions.
The test involves analyzing a DNA sample, typically obtained from a blood sample or FTA card, to look for specific changes (mutations) in the PRRT2 gene.
A healthcare provider or genetic counselor will interpret the results. A positive result indicates a mutation in the PRRT2 gene, which may explain the symptoms. Genetic counseling is recommended to understand the implications.
While not always mandatory, genetic counseling before and after the test is highly recommended. It helps understand the test, its implications, and the meaning of the results for the individual and their family.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp